All In Biotech

Drug Trial Radar · NCT05559671

Safety of the Herpes Zoster Subunit Vaccine in Lupus

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Non-inferiority Crossover Study Evaluating the Safety and Immunogenicity of the Herpes Zoster Subunit Vaccine in Patients With Systemic Lupus Erythematosus

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 224 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

224

Planned (sponsor's estimate)

Start

Dec 21, 2023

Primary completion

Feb 1, 2028

Study completion Feb 1, 2028

Sponsor

Lead sponsor
NYU Langone HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized, double-blind, placebo-controlled, non-inferiority crossover study will evaluate the Herpes Zoster Sunbit (HZ/su) vaccine in SLE patients in order to evaluate safety and immunogenicity in patients with variable baseline clinical activities, ages and immunosuppressant exposures. The investigators hypothesize that HZ/su administration will be non-inferior to placebo with respect to the risk of moderate or severe SLE flare(s) occurring within 24 weeks of receiving the first dose of the assigned treatment. In addition, the investigators hypothesize that immunogenicity of the vaccine in SLE patients will be at least 50% of levels observed in healthy subjects from prior large clinical trials.

Conditions

  • Systemic Lupus Erythematosus

Interventions

  • Herpes Zoster Subunit (HZ/su) VaccineBiological

    Manufactured by GSK Biologicals SA. Administered as two-time injection of 0.5 mL each at either weeks 0 and 8 or weeks 24 and 32.

  • PlaceboBiological

    Saline injection. Administered as two-time injection of 0.5 mL each at either weeks 0 and 8 or weeks 24 and 32.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of either Moderate or Severe Lupus Flares within 24 Weeks of First Dosing with HZ/su VaccineTime frame: Up to Week 48

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • NYU Langone Health

    New York, New York · Recruiting

  • Oklahoma Medical Research Foundation

    Oklahoma City, Oklahoma · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.